



## 10 Drugs Accounted for Nearly One-Third of Spending in Catastrophic Coverage in 2015

According to data recently released by the US Department of Health and Human Services, a mere 10 prescription drugs accounted for nearly 33% of all spending in catastrophic pharmacy costs. Two of the top three are related to Hep-C and the new medications that took the market by storm in 2015. The table below provides the overview of these top 10 drugs. As the cost of specialty medications continues to skyrocket, employers and plan sponsors need to remain vigilant in the effective management of their pharmacy plans.

10 Drugs Accounted for Nearly One-Third of Spending in Catastrophic Coverage, 2015					
Drug Name	Company Manufacturer*	Key Indications/Treats	FDA Approval Year	Average Price per Month**	Total Spending in Catastrophic Coverage
Harvoni	Gilead Sciences	Hepatitis C	2014	\$33,811	\$6,284,357,265
Relimid	Celgene	Cancers of the Blood	2005	\$11,516	\$1,718,263,750
Sovaldi	Gilead Sciences	Hepatitis C	2013	\$30,217	\$1,209,329,646
Humira	AbbVie, Inc.	Inflammatory Conditions	2002	\$3,930	\$1,205,270,252
Copaxone	Teva Pharms USA	Multiple Sclerosis	1996	\$5,642	\$1,143,986,768
Gleevec	Novartis	Various Cancers	2001	\$9,299	\$1,021,721,929
Enbrel	Amgen	Inflammatory Conditions	1998	\$3,540	\$938,254,647
Tecfidera	Biogen Idec, Inc.	Multiple Sclerosis	2013	\$5,595	\$735,215,799
Renvela	Sanofi	Chronic Kidney Disease	2007	\$1,158	\$675,261,441
Xtandi	Astellas	Prostate Cancer	2012	\$8,673	\$635,500,941
<b>Total</b>					<b>\$15,567,162,441</b>

\*The term "company" refers to New Drug Application holder or Biologics License Application holder.

\*\*Note: The price is the amount paid to the pharmacy by all payers. It is negotiated between the sponsors and their network pharmacies for the drug, or is the usual and customary price paid to out-of-network pharmacies. It is not adjusted for rebates or other price concessions. SOURCE: HHS Office of Inspector General analysis of Prescription Drug Event records, published in the OIG report, "High-Price Drugs Are Increasing Federal Payments for Medicare Part D Catastrophic Coverage" (OEI-02-16-00270).

For more information about best in class pharmacy techniques, please contact your Conner Strong & Buckelew account representative toll free at 1-877-861-3220 with any questions.



CONNER  
STRONG &  
BUCKLEW

INSURANCE | RISK MANAGEMENT | EMPLOYEE BENEFITS



[Click here to change your email preferences or unsubscribe from all communication.](#)